RNAi platform

Novel RNAi Platform

Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, Scientists at RXi have used an alternative approach to delivery, where drug-like as well as delivery properties are built into the RNAi compound itself. sd-rxRNA compounds are novel RNAi compounds with enhanced properties for therapeutic use.   RXI-109, an sd-rxRNA compound,  is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial in ophthalmology.